Altrova Health Closes Debt Settlement
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") is pleased to announce that it has closed a debt settlement involving the issuance of common shares in settlement of C$215,000 of bona fide indebtedness (the "Debt Settlement"). All dollar amounts in this news release are expressed in Canadian dollars unless otherwise indicated. The Debt Settlement did not result in
2026-09-29 5:02 PM EDT | Altrova Health Inc.
WELL Health Subsidiary WELLSTAR Announces Completion of Amalgamation and Expected Trading Date of "WSTR" on TSXV
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR") has completed the previously announced amalgamation (the "Transaction") with 1587818 B.C. L
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-09-29 3:30 PM EDT | WELL Health Technologies Corp.
At the Longevity Investors Conference in Gstaad, Investors Test Which Longevity Claims Hold Up
Zug, Switzerland--(Newsfile Corp. - September 29, 2026) - As longevity research moves from animal models into human trials, investors are asking a sharper question: what is science, and what is hype? That question shaped the seventh Longevity Investors Conference (LIC), held from 14 to 17 September 2026 at Le Grand Bellevue in Gstaad.
2026-09-29 11:46 AM EDT | Longevity Investors AG
Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line
Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new research-use offerings: Adia30M, AdiaClear, and AdiaEXO.
Soins de santé et hôpitaux, Santé
2026-09-29 8:00 AM EDT | Adia Med Inc.
Ian Mortimer Receives the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals, as the recipient of the 2026 Bloom Burton Award.
Technologies, Biotechnologies, Services bancaires d’investissement, Santé
2026-09-29 8:00 AM EDT | Bloom Burton & Co. Inc.
Edison Issues Report on iQSTEL (IQST)
London, United Kingdom--(Newsfile Corp. - September 29, 2026) - Edison issues report on iQSTEL (NASDAQ: IQST). iQSTEL has built a global telecommunications platform providing international voice and data termination services. The company has yet to achieve profitability and has had to rely on dilutive equity funding. Over the last decade, iQSTEL has grown rapidly through acquisitions and organic expansion to its current revenue run rate of over $0.5bn. Via commercial agreements with mor
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-09-29 7:53 AM EDT | Edison Group
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence
Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Through its wholly owned subsid
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-29 7:53 AM EDT | Rhelion Life Sciences Corp.
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Key Highlights Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-29 7:30 AM EDT | KALA Bio Inc.
BioHarvest Sciences Announces Share Repurchase Program
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in acc
Biotechnologies, Pharmaceutique, Santé
2026-09-29 7:00 AM EDT | BioHarvest Sciences Inc.
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee. Sherry Aulin is a f
Biotechnologies, Pharmaceutique, Santé
2026-09-29 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum combined unit commitment will be nego
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-29 3:05 AM EDT | TempraMed Technologies Ltd.
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering wil
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:49 PM EDT | TempraMed Technologies Ltd.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 20,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.03 per Unit for gross proceeds of up to $600,000. Each Unit consists of one (1) common share of the Company (each, a "Shar
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | PreveCeutical Medical Inc.
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
Montreal, Quebec--(Newsfile Corp. - September 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to provide a corporate update as the Company continues to execute on the strategic priorities outlined in its recent letter to shareholders. Since assuming the role
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | Defence Therapeutics Inc.
naia Relief Inc. Announces Strategic Partnership with Alumni-Perks to Expand Access to 24/7 Well-Being Support for Canadian University/College Alumni
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - naia Relief Inc. (TSXV: NAIA) (FSE: GU6) ("naia Relief" or the "Company"), a workplace well-being, resilience and performance company, is pleased to announce a strategic partnership with Alumni-Perks, an always-on engagement platform connecting Canadian colleges and universities with their alumni through exclusive benefits, events, stories and community-driven content. Through the partnership, naia Relief and
2026-09-28 7:00 AM EDT | Naia Relief Inc.
WELL Health Subsidiary WELLSTAR Announces Conditional Approval for TSXV Listing and Files Filing Statement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-09-28 6:00 AM EDT | WELL Health Technologies Corp.
Vector Science and Therapeutics Corp. Issues Options
Mequon, Wisconsin--(Newsfile Corp. - September 25, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors has approved the grant of 150,000 stock options (the "Options") to an Officer of the Company in accordance with the Company's stock option plan. The Options vest in 25% tranches over a three year period, have an exercise price of C$1.80 and are exercisable for a period of five years from the
2026-09-25 5:52 PM EDT | Vector Science and Therapeutics Corp. (formerly OpenSesame Acquisition Corp.)
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy
Toronto, Ontario--(Newsfile Corp. - September 25, 2026) - Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) ("Rhelion" or the "Company") an Ontario-based organization advancing innovation and research with
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-09-25 8:48 AM EDT | Rhelion Life Sciences Corp.
Izotropic Announces Non-Brokered Private Placement
British Columbia and Casablanca, Morocco--(Newsfile Corp. - September 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the intention to complete a non-brokered private placement (the "Offering") with of 750,000 units of the Company with a st
2026-09-25 8:00 AM EDT | Izotropic Corporation
Cheelcare Announces First Quarter Fiscal 2027 Financial Results
Markham, Ontario--(Newsfile Corp. - September 25, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced its financial results for the three months ended July 31, 2026. All figures are in CAD unless otherwise noted. Operational Highlights (Three Months Ended July 31, 2026) Companion reimbursement and market access: The Company continued to advance Companion's U.S. comm
2026-09-25 8:00 AM EDT | Cheelcare Inc.